Last reviewed · How we verify
Università Vita-Salute San Raffaele — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| desflurane, isoflurane, sevoflurane | desflurane, isoflurane, sevoflurane | marketed | ||||
| total intravenous anesthetics | total intravenous anesthetics | marketed | GABA-A receptor agonist / General anesthetic | GABA-A receptor | Anesthesiology | |
| Phosphocreatine | Phosphocreatine | phase 3 | Other |
Therapeutic area mix
- Anesthesiology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Università Vita-Salute San Raffaele:
- Università Vita-Salute San Raffaele pipeline updates — RSS
- Università Vita-Salute San Raffaele pipeline updates — Atom
- Università Vita-Salute San Raffaele pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Università Vita-Salute San Raffaele — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-vita-salute-san-raffaele. Accessed 2026-05-17.